TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Sep 16, 2019
He's bought and sold this at $43. They're Upjohn division is merging with Mylan and will spin it out. This will likely lead to the stock returning to the mid-$40's (Analysts’ price target is $42.75)
Photo of Bruce MurrayBruce Murray
No
Unlock Rating
$36.83

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 06, 2019
It has long term support levels. At a great spot, and it is consolidating well. Would take advantage of the pullback here. The risk is to go up not down.
Photo of Elliott FishmanElliott Fishman
No
Unlock Rating
$36.50

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 22, 2019

He would not buy it at this point. They recently agreed to by Mylan and with Teva have been challenged on pricing of their generic drugs. It has grown through cost cutting. Revenue growth is muted at best.

Photo of Gordon ReidGordon ReidUnlock Rating
$34.34

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 20, 2019
The US healthcare system is under attack by politicians until the election. Trump wants to put them out of business, so why mess with this space? Patent expirations are another hurdle.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$34.61

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Photo of Christine PooleChristine Poole
No
Unlock Rating
$35.20

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Pfizer Inc(PFE)

Jul 30, 2019
They were badly hit with the end of patent protection on several of their drugs. Viagara is coming up for expiry as well. He does not own it. It is a well run company and he continue to expect the dividend to grow as well. They announced an entry into the generic drug space, which may be confusing investors right now. He would hold off for a while.
Photo of Bruce MurrayBruce Murray
No
Unlock Rating
$38.79

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 26, 2019

Pfizer vs. Merck He owns both, which both score well in price momentum, high ROE, great balance sheet, pay a sustianble yield and are stable stocks. Merck has slightly better valuation metrics, but both stocks are very similar.

Photo of Jason MannJason Mann
Owned
Unlock Rating
$43.09

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 17, 2019
It's a machine that makes acquisitions which generate revenues worldwide. However, they lack growth and a presence in oncology though they recenly made an aquisition that can help growth. Expect modest growth, but limited downside too if a clinical trial fails. Good dividend and balance sheet. Good to hol.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$42.74

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 24, 2019
(A Top Pick Mar 11/19, Up 2%) It's holding. Thought we'd get a nice bounce, but it's treading water. It's more of a protection play, you don't need to jump in right away.
Photo of Elliott FishmanElliott Fishman
No
Unlock Rating
$41.95

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

May 23, 2019
It is the Bell Canada of the business. He just sold at 42-43. At 38-39 it is a safe buy. The largest in the sector. Don't have a lot of product coming off patents.
Photo of Bruce MurrayBruce Murray
No
Unlock Rating
$41.92

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 22, 2019
A successful drug company that has made many acquisitions that have led to good value and promising drugs. Healthcare stocks are under pressure in general as the Trump Administration is threatening to bring down drug costs. He thinks this will end and you will make good money holding.
Photo of Norman LevineNorman LevineUnlock Rating
$41.99

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 03, 2019
A long-term play. Low EPS growth of about 3.5-4%. Very large company. Don't have a lot of drugs that have exposure over 10%, except Prevnar. Not his favourite growth position. Diversity of assets. Need to do some M&A. Stable dividend. Only paying 15x. You can hold on to this.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$41.39

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Pfizer Inc(PFE)

Apr 23, 2019
A quality company that pays a good dividend. Look at it now during negative sentiment due to political pressure in America over high drug prices. Be cautious near-term, but do your homework on this now.
Photo of Colin StewartColin StewartUnlock Rating
$39.42

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Mar 25, 2019
Healthcare in general has outperformed in every bear market. A lot of it comes from large cap pharma companies. He prefers LLY-N. But there is no question that this one is interesting and has good management.
Photo of David FingoldDavid Fingold
No
Unlock Rating
$41.89

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Mar 21, 2019
It is a safe dividend play. He looks at total return so dividends are important but recommends you don’t get caught in a dividend trap where there is capital at risk. A lot of dividend payers have moved their valuations to historical high levels. You have to be careful.
Photo of Gordon ReidGordon ReidUnlock Rating
$42.35

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 226 to 240 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like